Trastuzumab biosimilar HLX02 versus reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a model-based economic evaluation for China

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
   PubMed Web of Science ®Google Scholar
• Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res Treat. 2016;159(3):565–573.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Smith IE. Management of small HER2-positive breast cancers. Lancet Oncol. 2010;11(12):1193–1199.
   PubMed Web of Science ®Google Scholar
• US FDA. Full prescribing information for herceptin (trastuzumab). [cited 2021 Oct 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf
   Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792.
   PubMed Web of Science ®Google Scholar
• Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–4274.
   PubMed Web of Science ®Google Scholar
• Lammers P, Criscitiello C, Curigliano G, et al. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets. Pharmaceuticals. 2014;7(9):943–953.
   Google Scholar
• Blackwell K, Gligorov J, Jacobs I, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Clin Breast Cancer. 2018;18(2):95–113.
   PubMed Web of Science ®Google Scholar
• Cherny N, Sullivan R, Torode J, et al. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe. Ann Oncol. 2016;27(8):1423–1443.
   PubMed Web of Science ®Google Scholar
• Fundytus A, Sengar M, Lombe D, et al. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey. Lancet Oncol. 2021;22(10):1367–1377.
   PubMed Web of Science ®Google Scholar
• Kim H, Alten R, Avedano L, et al. The future of biosimilars: maximizing benefits across immune-mediated inflammatory diseases. Drugs. 2020;80(2):99–113.
   PubMed Web of Science ®Google Scholar
• Xie L, Zhang E, Xu Y, et al. Demonstrating analytical similarity of trastuzumab biosimilar HLX02 to herceptin® with a panel of sensitive and orthogonal methods including a novel FcγRIIIa affinity chromatography technology. BioDrugs. 2020;34(3):363–379.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xu B, Zhang Q, et al. Global clinical trials validating bioequivalence with China-manufactured trastuzumab biosimilar, HLX02, and trastuzumab. Ann Oncol. 2018;29:ix13–ix20.
   Web of Science ®Google Scholar
• Zhu X, Ding Y, Yu Y, et al. A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects. Cancer Chemother Pharmacol. 2021;87(3):349–359.
   PubMed Web of Science ®Google Scholar
• Xu B, Zhang Q, Sun T, et al., Efficacy, safety, and immunogenicity of HLX02 compared with reference trastuzumab in patients with recurrent or metastatic HER2-positive breast cancer: a randomized phase III equivalence trial. BioDrugs. 2021;35(3):337–350.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Centrally authorised biosimilar medicines. [cited 2021 Oct 15]. Available from: https://www.ema.europa.eu/medicines/field_ema_web_categories%253Aname_field/Human/ema_group_types/ema_medicine/field_ema_medstatus/authorised-36/ema_medicine_types/field_ema_med_biosimilar/search_api_ggregation_ema_medicine_types/field_ema_med_biosimilar
   Google Scholar
• National medical products administration. the regulation of drug registration. [cited 2021 Oct 15]. Available from: https://www.nmpa.gov.cn/
   Google Scholar
• Stebbing J, Baranau YV, Baryash V, et al. Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial. Breast Cancer Res Treat. 2021;188(3):631–640.
   PubMed Web of Science ®Google Scholar
• Lammers PE, Dank M, Masetti R, et al. Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer. Br J Cancer. 2018;119(3):266–273.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2018;19(7):987–998.
   PubMed Web of Science ®Google Scholar
• Cheng L-J, Loke L, Lim EH, et al. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):449–456.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235–251.
   PubMed Web of Science ®Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• Ding D, Hu H, Liao M, et al. Cost-Effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of metastatic non-squamous non-small cell lung cancer. Adv Ther. 2020;37(5):2116–2126.
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang H, Shi J, et al. Trial-Based cost-utility analysis of icotinib versus gefitinib as second-line therapy for advanced non-small cell lung cancer in China. PLoS One. 2016;11(3):e0151846.
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of China. China population and employment statistics yearbook. [cited 2022 May 15]. Available from: http://www.stats.gov.cn
   Google Scholar
• Wu B, Ye M, Chen H, et al. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther. 2012;34(2):468–479.
   PubMed Web of Science ®Google Scholar
• The People’s Bank of China. announcement on the central parity of RMB exchange rate. [cited 2022 May 13]. Available from: http://www.pbc.gov.cn/zhengcehuobisi/125207/125217/125925/index.html
   Google Scholar
• The US Bureau of Labor Statistics. Consumer price index inflation calculator. [cited 2022 May 13]. Available from: https://www.bls.gov/data/inflation_calculator.htm
   Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690.
   PubMed Web of Science ®Google Scholar
• Weng X, Huang X, Li H, et al. First-Line treatment with atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer: a cost-effectiveness analysis. Am J Clin Oncol. 2020;43(5):340–348.
   PubMed Web of Science ®Google Scholar
• Beauchemin C, Letarte N, Mathurin K, et al. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada. J Med Econ. 2016;19(6):619–629.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang S, Zhang J. Effect of recombinant human granulocyte colony—stimulating factor on bone marrow depression in breast cancer patients after the chemotherapy. China Oncol. 2014;24:925–930.
   Google Scholar
• Eguchi K, Kabe J, Kudo S, et al. Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 1994;34(1):37–43.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Baik SH, Fendrick AM, et al. Comparing local and regional variation in health care spending. N Engl J Med. 2012;367(18):1724–1731.
   PubMed Web of Science ®Google Scholar
• Rui M, Shi F, Shang Y, et al. Economic evaluation of cisplatin plus gemcitabine versus paclitaxel plus gemcitabine for the treatment of first-line advanced metastatic triple-negative breast cancer in China: using Markov Model and Partitioned Survival Model. Adv Ther. 2020;37(9):3761–3774.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness — the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
   PubMed Web of Science ®Google Scholar
• Kay J. Are there benefits and risks to biosimilars from a patient perspective? Rheum Dis Clin North Am. 2019;45(3):465–476.
   PubMed Web of Science ®Google Scholar
• Lee S-M, Jung J-H, Suh D, et al. Budget impact of switching to biosimilar trastuzumab (ct-p6) for the treatment of breast cancer and gastric cancer in 28 European countries. Biodrugs. 2019;33(4):423–436.
   PubMed Web of Science ®Google Scholar
• Hara F, Tajima K, Tanabe K. Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. Future Oncol. 2019;15(12):1353–1361.
   PubMed Web of Science ®Google Scholar
• Teeple A, Ginsburg S, Howard L, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–609.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019;39(7):3971–3973.
   PubMed Web of Science ®Google Scholar
• Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: help from biosimilars - the explanatory case of bevacizumab. Eur J Cancer. 2021;143:40–42.
   PubMed Web of Science ®Google Scholar